ClinicalTrials.Veeva

Menu

Evaluation of Retinal and Vascular Features in Coats Disease After Intravitreal Injections of Ranibizumab

F

Federico II University

Status

Completed

Conditions

Coats Disease

Treatments

Drug: Ranibizumab Injection

Study type

Observational

Funder types

Other

Identifiers

NCT04310631
PT1003/20

Details and patient eligibility

About

This study evaluates the retinal and vascular features in patients affected by Coats disease under the effects of Ranibizumab intravitreal injections using optical coherence tomography and optical coherence tomography angiography

Full description

Coats disease is an idiopathic retinal vascular disorder, occurs in young males, and is characterized by retinal telangiactasias, numerous yellowish exudates in the subretinal space, macular edema, hemorrhages and, in advanced end-stage, by exudative retinal detachment.

Ranibizumab is a vascular endothelial growth factor antagonist represent an efficacy treatment acting on vascular hyperpermeability. The optical coherence tomography and optical coherence tomography angiography represent novel and non-invasive diagnostic techniques that allow a detailed analysis of retinal and vascular features. The study evaluates the changes in optical coherence tomography and optical coherence tomography angiography parameters at baseline and after three monthly injections of Ranibizumab in Coats disease.

Enrollment

5 patients

Sex

Male

Ages

19 to 30 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • age older than 18 years
  • diagnosis of Coats disease
  • treatment-naïve with Ranibizumab
  • absence of other vitreoretinal and vascular retinal diseases
  • absence of diabetes

Exclusion criteria

  • age younger than 18 years
  • No diagnosis of Coats disease
  • previous treatments with Ranibizumab
  • presence of vitreoretinal and vascular retinal diseases
  • presence of diabetes

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems